News

Back

Bioxodes announces the completion of the active phase of its First-in-Human study performed in healthy adult volunteers with Ir-CPI, a drug candidate for the prevention of thrombosis

April 29th 2021

BSCB Dev S.A

Bioxodes, a clinical stage biotechnology company announces today the completion of the active phase of its First-in-Human (FIH) study with Ir-CPI dedicated to the prevention of thrombosis. This FIH was a double blind, placebo controlled, single ascending dose trial performed in healthy adult male volunteers with Ir-CPI. Please discover the press release here.